J&J Janssen-Cilag helps end COVID-19

Our Partner Johnson&Johnson – Janssen Cilag is helping make a significant difference in ending the COVID-19 pandemic.

The investigational Janssen COVID-19 vaccine candidate leverages the Johnson&Johnson AdVac® vaccine platform, which was also used to develop and manufacture Janssen’s European Commission-approved Ebola vaccine regimen and construct its Zika, RSV, and HIV investigational vaccine candidates. Janssen’s AdVac® technology has been used to vaccinate more than 114,000 people to date across the Johnson&Johnson investigational vaccine programs.